Optimizing antimicrobial use and combating bacterial resistance: Benchmarking and beyond

Antibiotic Optimization: Concepts and Strategies in Clinical Practice

Volumn , Issue , 2004, Pages 181-207

  Bhavnani, Sujata M ^a   Ambrose, Paul G ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80855143851     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (47)

1. Deming WE. Out of the Crisis. Cambridge: Massachusetts Institute of Technology Center for Advanced Engineering Study, 1986.
2. Woomer N, Long CO, Anderson C, Greenberg EA. Benchmarking in home health care: a collaborative approach. Caring 1999; 18:22–28.
3. Narong MN, Thongpiyapoom S, Thaikul N, Jamulitrat S, Kasatpibal N. Surgical site infections in patients undergoing major operations in a university hospital: using standardized infection ratio as a benchmarking tool. Am J Infect Control 2003; 31:274–279.
4. Stevenson KB. Regional data set of infection rates for long-term care facilities: description of a valuable benchmarking tool. Am J Infect Control 1999; 27:20–26.
5. Rudy EB, Lucke JF, Whitman GR, Davidson LJ. Benchmarking patient outcomes. J Nurs Scholarsh 2001; 33:185–189.
6. Bissell MG. The effect of benchmarking clinical practice with the clinical laboratory. Clin Lab Med 1999; 19:867–876.
7. Fridkin SK, Lawton R, Edwards JR, Tenover FC, McGowan JE, Gaynes RP. Intensive Care Antimicrobial Resistance Epidemiology Project. National Nosocomial Infections Surveillance Systems Hospitals. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002; 8:702–707.
8. Bhavnani SM, Callen WA, Forrest A, Gilliland KK, Collins DA, Paladino JA, Schentag JJ. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health Syst Pharm 2003; 60: 1962–1970.
9. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5: 1033–1048.
10. McGowan JE Jr. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull NY Acad Med 1987; 63:253–268.
11. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23:1020–1025.
12. Roberts NJ, Douglas RG. Gentimicin use and Pseudomonas and Serratia resistance: effect of a surgical prophylaxis regimen. Antimicrob Agents Chemother 1978; 13:214–220.
13. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Diagn Microbiol Infect Dis 1992; 15(2 suppl):375–425.
14. Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, Gaynes RP, McGowan JE Jr. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001; 135:175–183.
15. Lesch CA, Itokazu GS, Danziger LH, Weinstein RA. Multihospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001; 41:149–154.
16. Johnson CK, Polk R. Antimicrobial use in U.S hospitals and methicillin-resistant Staphylococcus aureus (MRSA) [abstr no. K-1399]., 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 16, 2003, Chicago.
17. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23:118–124.
18. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N, Marks S, Burns JM, Dominick D, Lim M. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella JAMA 1998; 280: 1233–1237.
19. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae Infect Control Hosp Epidemiol 2000; 21:455–458.
20. Phelps CE. Bug/drug resistance: sometimes less is more. Med Care 1989; 27:194–203.
21. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065–1078.
22. Himmelberg CJ, Pleasants RA, Weber DJ, Kessler JM, Samsa GP, Spivey JM, Morris TL. Use of antimicrobial drugs in adults before and after removal of a restriction policy. Am J of Hosp Pharm 1991; 48:1220–1227.
23. Briceland LL, Nightingale CH, Quintiliani R, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med 1988; 148:2019–2022.
24. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155:1273–1276.
25. National Nosocomial Infection Surveillance (NNIS) System Report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29:404–421.
26. Bergman U, Grimsson A, Wahba AHW, Westerholm B. Studies in Drug Utilization. European series, no. 8., Copenhagen: WHO Regional Office for Europe, 1979.
27. Westerholm B. Consumption of Drugs: Report on a Symposium. Euro 3102. Copenhagen: WHO Regional Office for Europe, 1970.
28. Enzweiler K, Lorenz K, Bosso J, White R. Agreement among different markers of antibiotic use over an eight-year period., 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Dec 16–19, 2001, Chicago.
29. Bonapace CR, Lorenz KR, Bosso JA, White RL. Use of different measures of drug usage in assessing antibiotic use/susceptibility relationships., 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 17–20, 2000, Toronto.
30. Cars O, Molstad S, Melander A. Variation in antibiotic use in European Union. Lancet 2001; 357:1851–1853.
31. Molstad S, Lundborg CS, Karlsson AK, Cars O. Antibiotic prescription rates vary markedly between 13 European countries. Scand J Infect Dis 2002; 34:366–371.
32. Bhavnani SM. Benchmarking in health-system pharmacy: current research and practical applications. Am J Health Syst Pharm 2000; 57(suppl 2):S13-S20.
33. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18:275–291.
34. Patton KA. Role of JCAHO standards and clinical practice guidelines in promoting appropriate antimicrobial use. Am J Health Syst Pharm 2002; 59(8 suppl 3):S16-S18.
35. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Archibald LK, Gaynes RP, Tenover FC. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999; 29: 245–252.
36. Fridkin SK. The challanges and value of monitoring antimicrobial use and resistance [abstr no. K-1084]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 27–30, 2002, San Diego.
37. Hill HA, Haber MJ, McGowan JE Jr, Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, Project ICARE Hospitals. A link between quinolone use and resistance in P. aeruginosa [abstr no. 495]. 39th Annual Meeting of the Infectious Diseases Society of America, Oct 25–28, 2001, San Francisco.
38. Johnson CK, Davis S, Polk R. No association between changes in hospital fluoroquinolone use and changes in rates of fluoroquinolone-resistant P. aeruginosa [abstr no. K-1427]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 14–17, 2003, Chicago.
39. Schentag JJ, Paladino JA, Birmingham MC, Zimmer G, Carr JR, Hanson SC. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. J Pharm Tech 1995; 11:203–210.
40. Rifenburg RP, Paladino JA, Hanson SC, Tuttle JA, Schentag JJ. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health Syst Pharm 1996; 53: 2054–2062.
41. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH, and the National Nosocomial Resistance Surveillance Group. A nationwide, multicenter, case- control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36:145–158.
42. Bhavnani SM, Hammel JP, Forrest A, Jones RN, Ambrose PG. Relationships between patient- and institution-specific variables and decreased susceptibility of gram-negative pathogens. Clin Infect Dis 2003; 37:344–350.
43. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49:999–1005.
44. Sader HS, Biedenbach DJ, Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48, 440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn Microbiol Infect Dis 2003; 47:361–364.
45. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista AT, Karlowsky JA. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002; 34:S4-S16.
46. Rhomberg PR, Jones RN. MYSTIC Program (USA) Study Group. Antimicrobial spectrum of activity for meropenom and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 2003; 47:365–372.
47. Hammel JP, Bhavnani SM, Ambrose PG, Jones RN, Forrest A, Piedmonte MR. Comparison of censored regression vs standard regression analyses for modeling relationships between minimum inhibitory concentrations and patient- and institution- specific variables., 104th American Society for Clinical Pharmacology and Therapeutics, April 2003, Washington, DC.